Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent.
Journal
Current opinion in lipidology
ISSN: 1473-6535
Titre abrégé: Curr Opin Lipidol
Pays: England
ID NLM: 9010000
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
12
7
2023
pubmed:
17
3
2023
entrez:
16
3
2023
Statut:
ppublish
Résumé
To highlight critical aspects of inclisiran, from preclinical studies to current recommendations in clinical practice and future perspectives. Inclisiran use has been recently approved by regulatory agencies. The evidence of its efficacy and safety makes it a promising therapeutical tool for treating dyslipidemias. The link between LDL-cholesterol and atherosclerotic cardiovascular disease (ASCVD) is well established. Inclisiran, a small interfering RNA, has proven its safety and efficacy in reducing LDL-cholesterol, and FDA and EMA have recently approved its use. This review illustrates the development, structure, and mechanism of action of inclisiran and provides information regarding its efficacy, safety, and current recommendation in clinical practice. Moreover, it provides key information on the most recent/ongoing trials that will help us to implement the use of inclisiran in clinical practice.
Identifiants
pubmed: 36924354
doi: 10.1097/MOL.0000000000000877
pii: 00041433-990000000-00031
doi:
Substances chimiques
Cholesterol, LDL
0
ALN-PCS
0
RNA, Small Interfering
0
Proprotein Convertase 9
EC 3.4.21.-
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
133-140Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41:111–188.
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38:2459–2472.
Mihaylova B, Emberson J, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380:581–590.
Giordano S, Spadafora L, Biondi-Zoccai G, Bernardi M. Magnitude of low-density lipoprotein reduction and impact on major cardiovascular outcomes. J Cardiovasc Pharmacol 2023; 81:15–17.
Qamar A, Libby P. Low-density lipoprotein cholesterol after an acute coronary syndrome: how low to go? Curr Cardiol Rep 2019; 21:77.
Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42:3227–3337.
Indolfi C, Chiariello M, Avvedimento EV. Selective gene therapy for proliferative disorders: sense and antisense. Nat Med 1996; 2:634–635.
Gareri C, Polimeni A, Giordano S, et al. Antisense oligonucleotides and small interfering RNA for the treatment of dyslipidemias. J Clin Med 2022; 11:3884.
Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34:154–156.
Schwartz GG, Steg PG, Szarek M, et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379:2097–2107.
Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376:1713–1722.
Seidah NG. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. Curr Pharm Des 2013; 19:3161–3172.
De Rosa S, Iaconetti C, Eyileten C, et al. Flow-responsive noncoding RNAs in the vascular system: basic mechanisms for the clinician. J Clin Med 2022; 11:459.
Iaconetti C, Gareri C, Polimeni A, Indolfi C. Noncoding RNAs: the “dark matter” of cardiovascular pathophysiology. Int J Mol Sci 2013; 14:19987–20018.
Alshaer W, Zureigat H, Al Karaki A, et al. siRNA: mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol 2021; 905:174178.
Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 2017; 376:41–51.
Pratt AJ, MacRae IJ. The RNA-induced silencing complex: a versatile gene-silencing machine. J Biol Chem 2009; 284:17897–17901.
Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 2008; 105:11915–11920.
Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014; 383:60–68.
Ray KK. Impact of a single or two dose regimen of inclisiran, a novel siRNA inhibitor to PCSK9 on time averaged reductions in LDL-C over 1 year. ORION 1. Paper presented at: European Society of Cardiology (ESC) Congress 2017 (August), pp. 26–30. Barcelona. Spain: FP Number; 2017. p. 3064.
Ray KK, Wright RS, Kallend D, et al. ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020; 382:1507–1519.
Raal FJ, Kallend D, Ray KK, et al. ORION-9 Investigators. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med 2020; 382:1520–1530.
Wright RS, Ray KK, Raal FJ, et al. ORION Phase III Investigators. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol 2021; 77:1182–1193.
Ray KK, Raal FJ, Kallend DG, et al. ORION Phase III investigators. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J 2023; 44:129–138.
Ray K, Troquoy R, Visseren F, et al. Efficacy and safety of twice yearly subcutaneous lnclisiran in patients with high cardiovascular risk and elevated low-density lipoprotein cholesterol up to 4 years: the ORION-3 Trial. American Heart Association (AHA) Scientific Sessions 2022. 5–7 November 2022. Chicago, IL.
NCT03159416. A Study of inclisiran in participants with renal impairment compared to participants with normal renal function (ORION-7). Available at: https://clinicaltrials.gov/ct2/show/NCT03159416 . [Accessed 1 January 2023]
Kallend D, Stoekenbroek R, He Y, et al. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. J Clin Lipidol 2022; 16:208–219.
NCT04774003. Study of pharmacokinetics, pharmacodynamics, safety and tolerability of inclisiran in Chinese participants with elevated serum LDL-C (ORION-14). Available at: https://clinicaltrials.gov/ct2/show/NCT04774003 . [Accessed 1 January 2023]
NCT04666298. Study of efficacy and safety of inclisiran in Japanese participants with high cardiovascular risk and elevated LDL-C. Available at: https://clinicaltrials.gov/ct2/show/nct04666298 . [Accessed 1 January 2023]
NCT04765657. Study of efficacy and safety of inclisiran in Asian participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD high risk and elevated low density lipoprotein cholesterol (LDL-C). Available at: https://clinicaltrials.gov/ct2/show/NCT04765657 . [Accessed 1 January 2023]
FDA approves add-on therapy to lower cholesterol among certain high-risk adults. Available at: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-addtherapy-lower cholesterol among certain high-risk adults. [Accessed 03 December 2022]
EuropeanMedicinesAgency: Leqvio (inclisiran). Available at: https://www.ema.europa.eu/en/medicines/human EPAR/leqvio. [Accessed 1 January 2023]
NCT04873934. Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome (V-INCEPTION). Available at: https://clinicaltrials.gov/ct2/show/NCT04873934 .
NCT05587621. Intensive Lipid-lowering in Patients With STEMI (JaZ). Available at: https://clinicaltrials.gov/ct2/show/NCT05587621 . [Accessed 1 January 2023]
NCT03851705. A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (ORION-5). Available at: https://www.clinicaltrials.gov/ct2/show/NCT03851705 . [Accessed 1 January 2023]
NCT04659863. Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia (ORION-13). Available at: https://clinicaltrials.gov/ct2/show/NCT04659863 . [Accessed 1 January 2023]
NCT04652726. Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia (ORION-16). Available at: https://clinicaltrials.gov/ct2/show/NCT04652726 . [Accessed 1 January 2023]
NCT05118230. Study to assess the real world effectiveness of inclisiran in Chinese adult patients with primary hypercholesterolemia or mixed dyslipidemia. Available at: https://clinicaltrials.gov/ct2/show/NCT05118230 . [Accessed 1 January 2023]
NCT03060577. An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol (ORION-3). Available at: https://clinicaltrials.gov/ct2/show/NCT03060577 . [Accessed 1 January 2023]
NCT05399992. Study Evaluating Effectiveness and Adherence of Inclisiran Plus Standard of Care (SoC) Lipid-lowering Therapy Compared to SoC in ASCVD (VICTORION REAL). Available at: https://www.clinicaltrials.gov/ct2/show/NCT05399992 . [Accessed 1 January 2023]
NCT05004675. Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients (LIBerate-VI). Available at: https://www.clinicaltrials.gov/ct2/show/NCT05004675 . [Accessed 1 January 2023]
NCT03705234. A randomized trial assessing the effects of inclisiran on clinical outcomes among people with cardiovascular disease (ORION-4). Available at: https://www.clinicaltrials.gov/ct2/show/NCT03705234 . [Accessed 1 January 2023]
NCT05030428. Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P). Available at: https://www.clinicaltrials.gov/ct2/show/NCT05030428 . [Accessed 1 January 2023]
NCT05360446. Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Nonobstructive Coronary Artery Disease Without Previous Cardiovascular Events (V-PLAQUE). Available at: https://www.clinicaltrials.gov/ct2/show/NCT05360446 . [Accessed 1 January 2023]
NCT05639218. Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques. Available at: https://www.clinicaltrials.gov/ct2/show/NCT05639218 . [Accessed 1 January 2023]